|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
AU2002253795B2
(en)
|
2000-11-30 |
2007-02-01 |
The Children's Medical Center Corporation |
Synthesis of 4-Amino-Thalidomide enantiomers
|
|
US7091353B2
(en)
*
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
DE60332358D1
(de)
*
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US6943249B2
(en)
|
2003-03-17 |
2005-09-13 |
Ash Stevens, Inc. |
Methods for isolating crystalline Form I of 5-azacytidine
|
|
US6887855B2
(en)
|
2003-03-17 |
2005-05-03 |
Pharmion Corporation |
Forms of 5-azacytidine
|
|
WO2005007162A1
(en)
*
|
2003-07-10 |
2005-01-27 |
Vertex Pharmaceuticals Incorporated |
Compounds augmenting the activity of antibacterial agents
|
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
KR20120039065A
(ko)
*
|
2003-12-02 |
2012-04-24 |
셀진 코포레이션 |
혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물
|
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
BRPI0509019A
(pt)
*
|
2004-03-22 |
2007-08-07 |
Celgene Corp |
métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
|
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
EP1744749A4
(en)
*
|
2004-04-14 |
2009-04-22 |
Celgene Corp |
METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES
|
|
US20050239842A1
(en)
*
|
2004-04-23 |
2005-10-27 |
Zeldis Jerome B |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
|
CA2565447A1
(en)
*
|
2004-05-05 |
2005-12-01 |
Celgene Corporation |
Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
|
|
BRPI0514865A
(pt)
*
|
2004-09-03 |
2008-06-24 |
Celgene Corp |
processo para preparar um composto
|
|
JP2008520731A
(ja)
*
|
2004-11-23 |
2008-06-19 |
セルジーン・コーポレーション |
中枢神経系傷害を治療及び管理するための、免疫調節性化合物を使用した方法及び組成物
|
|
HRP20130102T1
(hr)
*
|
2005-06-30 |
2013-03-31 |
Celgene Corporation |
Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
|
|
US20070066512A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
|
RU2453556C2
(ru)
|
2005-11-09 |
2012-06-20 |
Протеоликс, Инк. |
Соединения для ингибирования фермента
|
|
ZA200804717B
(en)
*
|
2005-12-29 |
2010-02-24 |
Anthrogenesis Corp |
Improved composition for collecting and preserving a placental stem cells and methods of using the composition
|
|
WO2007136640A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
RU2450016C2
(ru)
|
2006-06-19 |
2012-05-10 |
Протеоликс, Инк. |
Пептидные эпоксикетоны для ингибирования протеасомы
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
DK2428513T3
(en)
|
2006-09-26 |
2017-08-21 |
Celgene Corp |
5-substituted quinazolinone derivatives as anti-cancer agents
|
|
WO2008057196A2
(en)
*
|
2006-10-19 |
2008-05-15 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
|
|
AU2008305581C1
(en)
|
2007-09-26 |
2014-12-11 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
|
KR20170040374A
(ko)
|
2007-10-04 |
2017-04-12 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
|
EP2211870A1
(en)
*
|
2007-11-01 |
2010-08-04 |
Celgene Corporation |
Cytidine analogs for treatment of myelodysplastic syndromes
|
|
CA2712724A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Celgene Corporation |
Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency
|
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
EP3782612B1
(en)
|
2008-05-15 |
2023-11-08 |
Celgene Corporation |
Oral formulations of cytidine analogs and methods of use thereof
|
|
AU2009308516B2
(en)
|
2008-10-21 |
2016-08-25 |
Onyx Therapeutics, Inc. |
Combination therapy with peptide epoxyketones
|
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
PE20110547A1
(es)
|
2008-10-29 |
2011-08-04 |
Celgene Corp |
Compuestos de isoindolina con actividad anticancerigena
|
|
WO2010054833A1
(de)
*
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Intermediate und orale darreichungsformen enthaltend lenalidomid
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
WO2010093434A1
(en)
|
2009-02-11 |
2010-08-19 |
Celgene Corporation |
Isotopologues of lenalidomide
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
AU2010249615B2
(en)
|
2009-05-19 |
2013-07-18 |
Celgene Corporation |
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
|
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
|
CN101696205B
(zh)
|
2009-11-02 |
2011-10-19 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
|
JP5919196B2
(ja)
|
2009-11-13 |
2016-05-18 |
オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
転移抑制のためのペプチドエポキシケトンの使用
|
|
US8716252B2
(en)
|
2009-12-22 |
2014-05-06 |
Celgene Corporation |
(Methylsulfonyl) ethyl benzene isoindoline derivatives and their pharmaceutical uses
|
|
EP2536706B1
(en)
|
2010-02-11 |
2017-06-14 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
CA2791651C
(en)
|
2010-03-01 |
2019-08-20 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
NZ602872A
(en)
|
2010-04-07 |
2014-05-30 |
Onyx Therapeutics Inc |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
DK2556145T3
(en)
|
2010-04-07 |
2016-11-07 |
Anthrogenesis Corp |
Angiogenesis using placental stem cells
|
|
US20110301199A1
(en)
*
|
2010-06-07 |
2011-12-08 |
Telik, Inc. |
Compositions and methods for treating myelodysplastic syndrome
|
|
US8759303B2
(en)
|
2010-06-07 |
2014-06-24 |
Telik, Inc. |
Compositions and methods for treating myelodysplastic syndrome
|
|
ES2664872T3
(es)
|
2010-06-18 |
2018-04-23 |
Taiho Pharmaceutical Co., Ltd |
Moduladores PRPK-TPRKB y sus usos
|
|
WO2012092485A1
(en)
|
2010-12-31 |
2012-07-05 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory rna molecules
|
|
MX347928B
(es)
|
2011-01-10 |
2017-05-19 |
Celgene Corp |
Derivados de fenetilsulfona isoindolina y su uso.
|
|
WO2012106299A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
|
JP5959543B2
(ja)
|
2011-03-11 |
2016-08-02 |
セルジーン コーポレイション |
３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用
|
|
AU2012236655B2
(en)
|
2011-03-28 |
2016-09-22 |
Deuterx, Llc, |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
|
MX2013010945A
(es)
|
2011-03-31 |
2014-03-12 |
Celgene Internat Sarl |
Sintesis de 5 - azacitidina.
|
|
CA2834535A1
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
ES2707579T3
(es)
|
2011-06-01 |
2019-04-04 |
Celularity Inc |
Tratamiento del dolor usando citoblastos placentarios
|
|
WO2012177678A2
(en)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues of pomalidomide
|
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
|
WO2013040120A1
(en)
|
2011-09-14 |
2013-03-21 |
Celgene Corporation |
Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
|
|
RS60415B1
(sr)
|
2011-12-27 |
2020-07-31 |
Amgen (Europe) GmbH |
Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
|
|
WO2013126394A1
(en)
|
2012-02-21 |
2013-08-29 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
ES2872967T3
(es)
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
|
JP2015524394A
(ja)
|
2012-07-09 |
2015-08-24 |
オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
|
|
DK2882737T3
(da)
|
2012-08-09 |
2019-05-13 |
Celgene Corp |
Fast form af (s)-3-(4-((4-morpholinmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorid
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
CN105102612B
(zh)
|
2012-12-06 |
2020-11-17 |
恩立夫克治疗有限责任公司 |
治疗性凋亡细胞制剂、其制备方法以及其用途
|
|
CA2935495C
(en)
|
2013-01-14 |
2021-04-20 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
|
EP2968334A4
(en)
|
2013-03-14 |
2016-08-03 |
Deuterx Llc |
3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
|
|
CN105246480A
(zh)
|
2013-04-02 |
2016-01-13 |
细胞基因公司 |
使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物
|
|
KR20160004299A
(ko)
|
2013-04-09 |
2016-01-12 |
릭스트 바이오테크놀로지, 인코포레이티드 |
옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
|
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
UA117141C2
(uk)
|
2013-10-08 |
2018-06-25 |
Селджин Корпорейшн |
Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
|
|
TW201540323A
(zh)
|
2014-01-15 |
2015-11-01 |
Celgene Corp |
３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
|
|
AU2015210999A1
(en)
|
2014-01-29 |
2016-07-21 |
Otsuka Pharmaceutical Co., Ltd. |
Device-based risk management of a therapeutic
|
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
|
EP3171870B1
(en)
*
|
2014-07-24 |
2021-10-20 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
|
|
KR20170042598A
(ko)
|
2014-08-22 |
2017-04-19 |
셀진 코포레이션 |
항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US10488411B2
(en)
*
|
2015-05-01 |
2019-11-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inflammasome activation in myelodysplastic syndromes
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
HUE044698T2
(hu)
|
2015-08-17 |
2019-11-28 |
Kura Oncology Inc |
Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
|
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
|
BR112018075206A2
(pt)
*
|
2016-06-06 |
2019-03-19 |
Celgene Corporation |
tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
|
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
|
EP3493809B1
(en)
*
|
2016-08-03 |
2023-08-23 |
Celgene Corporation |
Enasidenib for treatment of myelodysplastic syndrome
|
|
EP4324477A3
(en)
|
2016-12-08 |
2024-05-22 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for modulation of immune response
|
|
WO2018129533A1
(en)
|
2017-01-09 |
2018-07-12 |
Shuttle Pharmaceuticals, Llc |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
JP2021519337A
(ja)
*
|
2018-03-26 |
2021-08-10 |
シー４ セラピューティクス， インコーポレイテッド |
Ｉｋａｒｏｓの分解のためのセレブロン結合剤
|
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
CN116887844A
(zh)
*
|
2021-01-18 |
2023-10-13 |
活跃生物技术有限公司 |
用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐
|
|
KR20230133317A
(ko)
*
|
2021-01-18 |
2023-09-19 |
액티브 바이오테크 에이비 |
골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
|